GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered as a booster in people aged ≥4 years.

dTpa — diphtheria-tetanus-acellular pertussis combination vaccine (reduced antigen formulation)

Each 0.5 mL monodose vial or pre-filled syringe contains:

  • ≥2 IU diphtheria toxoid
  • ≥20 IU tetanus toxoid
  • 8 µg pertussis toxoid
  • 8 µg filamentous haemagglutinin
  • 2.5 µg pertactin

Adsorbed onto 0.5 mg aluminium as aluminium hydroxide and aluminium phosphate.

Also contains traces of:

  • formaldehyde
  • polysorbate 80
  • glycine

For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018


diphtheria-tetanus-acellular pertussis vaccine, reduced antigen content formulation
international units